Low dose estrogen progestin pill is better than cyclical progestin as medical management of abnormal uterine bleeding due to ovulatory dysfunction in premenopausal women

Authors

  • Tarafdar Runa Laila Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Khairun Nahar Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Sheikh Salahuddin Ahmed Department of Medicine, New Castle University Medicine Malaysia, Johor, Malaysia
  • Bidisha Chakma Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Walida Afrin Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Samira Moyeen Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Hasina Khatun Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Shakeela Ishrat Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh https://orcid.org/0000-0002-8568-0417

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20241281

Keywords:

Abnormal uterine bleeding, Anovulatory type, Low dose estrogen-progestin pill, Norethisterone

Abstract

Background: In abnormal uterine bleeding due to ovulation dysfunction, unopposed estrogen causes persistent proliferative or hyperplastic endometrium and periods of amenorrhea followed by excessive bleeding. This is managed medically by cyclical use of some hormonal agents. The aim of the study was to compare the effectiveness and acceptability of cyclical progestin alone and low dose estrogen progestin pill as medical management of AUB-O in premenopausal women.

Methods: The study composed of 57 premenopausal women with anovular type of bleeding. The study participants were randomly allocated to take either norethisterone 10 mg daily from 16th to 25th day of menstrual cycle or low dose estrogen progesterone pill, one pill daily from 1st day of menstrual cycle up to 24th day. These patients were followed up after three and six months to assess subjectively the persistence of abnormal uterine bleeding, patient’s satisfaction, need for hysterectomy and any side effects.

Results: The symptomatic improvement was more apparent with estrogen progestin pill than cyclical norethisterone. More patients chose hysterectomy in the norethisterone group because they were not satisfied with medical management.

Conclusions: Symptomatic improvement is more with low dose estrogen progestin pill than cyclical norethisterone in women with AUB-O. More women decline hysterectomy as they accept estrogen progestin pill.

References

Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.

Mahajan N, Aggarwal M, Bagga A. Health issues of menopausal women in North India. J Midlife Health. 2012;3:84-7.

Vitale SG, Watrowski R, Barra F, D'Alterio MN, Carugno J, Sathyapalan T, et al. Abnormal Uterine Bleeding in Perimenopausal Women: The Role of Hysteroscopy and its Impact on Quality of Life and Sexuality. Diagnostics (Basel). 2022;12(5):1176.

Lacey JVJ, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63(1):39-44.

Hickey M, Salamonsen LA. Endometrial structural and inflammatory changes with exogenous progestogens. Trend Endocrinol Metab. 2008;19(5):167-74.

Hickey M, Jenny M, Higham J M, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Datab Syst Rev. 2012;9:CD001895.

Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990;30(4):353-6.

Dunphy BC, Goerzen J, Greene CA, Ronde SDL, Seidel J, Ingelson B. A double-blind randomized study comparing danazol and medroxyprogesterone acetate in the management of menorrhagia. J Obstet Gynaecol. 1998;18(6):553-5.

Bender RA. Medroxyprogesterone Acetate for abnormal uterine bleeding due to ovulatory dysfunction: The effect of 2 different-duration regimens. Med Sci Monit. 2022;28:e936727.

Lethaby A, Wise MR, Waterings MAZ, Rodriguez MB, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2019, 2019(2):34-7.

Rodriguez MB. Management of abnormal uterine bleeding associated with ovulatory dysfunction. Am Coll Obstet Gynecol. 2013;122(1):176-85.

Singh S, Best C, Dunn S, Leyland N, Wolfman WL. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can. 2013;35(5):473-9.

Di Bella ZIK, De Mello Bianchi AMH, De Araujo FF, Sartori MGF, Girão MJBC. Contraception and family planning at the extreme of reproductive life - climacteric. Rev Assoc Medica Bras. 2016;62(5):454-7.

Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152(2):133-7.

MacGregor EA. Menstrual and perimenopausal migraine: a narrative review. Maturitas. 2020;142:24-30.

Gambacciani M, Monteleone P, Ciaponi M, Sacco A, Genazzani AR. Effects of oral contraceptives on bone mineral density. Treat Endocrinol. 2004;3(3):191-6.

Cibula D, Gompel A, Mueck AO, Vecchia CL, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. Hum Reprod. 2010;16(6):631-50.

Downloads

Published

2024-05-04

Issue

Vol. 13 No. 6 (2024): June 2024

Section

Original Research Articles